Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

A Clinical Study of Recombinant Oncolytic Adenovirus L-IFN Injection With Multiple Administration Routes in Relapsed/Refractory Solid Tumors (YSCH-01)

10. november 2026 opdateret af: Shanghai Fengxian District Central Hospital

Sikkerhed og effektivitet af rekombinant L-IFN adenovirusinjektion i recidiverende/refraktære faste tumorer: en enkelt/multicenter, dosisforøgende, kohorteforlængelse klinisk undersøgelse

This is an open-label, dose-escalation study evaluating the safety and tolerability of Recombinant Oncolytic Adenovirus L-IFN Injection (YSCH-01) administered via different routes, including intratumoral injection and aerosol therapy, in patients with advanced solid tumors. The purpose of this study is to assess the safety and tolerability of Recombinant L-IFN adenovirus injectionand to determine the recommended phase 1 dose for further study. The study will also evaluate antitumor activity, objective response rate, pharmacokinetics and virus shedding of Recombinant L-IFN adenovirus injection

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This is an investigator-initiated, open-label study evaluating Recombinant Oncolytic Adenovirus L-IFN Injection as a single agent administered via different routes, including intratumoral (IT) injection and aerosol therapy, in participants with advanced solid tumors.The study is a single agent dose escalation which will use a 3+3 design to evaluate escalating doses of Recombinant L-IFN adenovirus injection. Total enrollment will depend on the toxicities and/or activity observed, with approximately19-28 evaluable participants enrolled.

The primary study objective is to determine the safety, tolerability, and maximum tolerated dose (MTD) of intratumoral administration of Recombinant oncolytic adenovirus L-IFN injection as a single agent. Secondary objectives will assess efficacy overall response rate, as well as disease control rate, progression free survival, duration of response, and anti-tumor immune responses.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

25

Fase

  • Tidlig fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kina, 201406
        • Shanghai Fengxian District Central Hospital

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 75 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Male or female aged ≥ 18 and ≤ 75 years;
  2. Patients with advanced malignant solid tumors, histologically or cytologically confirmed, who have failed standard therapy, have no standard therapy, are not eligible for standard therapy at this stage, or have refused standard therapy;
  3. At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1), the length of non-lymph node lesion ≥10 mm or the short diameter of lymph node lesion ≥15 mm according to CT or MRI cross-sectional images;CT scan of the longest axis of measurable lesions ≥10 mm (CT scan thickness ≤5 mm);
  4. There were injectable tumor lesions that met the requirements of the current dose group, including superficial lesions and deep lesions that could be injected under the guidance of B-ultrasound /CT;
  5. ECOG score of 0 ~ 2;
  6. Sufficient hematopoietic capacity: ANC ≥1.0 ×10^9/L (no short-acting albino within 1 week, no long-acting albino within 2 weeks), platelet count ≥75 ×10^9/L, HGB > 80 g/L (no blood transfusion within 2 weeks);
  7. Adequate liver and kidney function: AST and ALT ≤3 times ULN in patients without liver metastasis, ≤5 times ULN in patients with liver metastasis; Total bilirubin ≤1.5 ULN (excluding hyperbilirubinemia or hyperbilirubin of non-liver origin);Creatinine ≤2.0 ULN and creatinine clearance and creatinine clearance ≥40 mL/min;
  8. Eligible and fertile patients (male and female) must agree to use a reliable contraceptive method during the trial and for at least 90 days after the last dose; Women of childbearing age (15-49 years) must have a negative pregnancy test within 7 days before starting treatment;
  9. PT or INR <1.5 ULN, and APTT <1.5 ULN;
  10. Expect to live at least 12 weeks;

Exclusion Criteria:

  1. Received any antineoplastic therapy within 2 weeks prior to initial treatment;

  2. Systemic diseases that have not been stably controlled after treatment, such as diabetes, serious organic cardiovascular and cerebrovascular diseases, cardiac insufficiency, hypertension, heart block above ⅱ degree, myocardial infarction within 6 months, cerebral infarction within 6 months, etc.

  3. Pregnancy or lactation;

  4. Uncontrolled infectious diseases, such as baseline HBV DNA≥2000 IU/ml, anti-HIV positive, HCV-RNA positive;

  5. Other active infections of significant clinical significance;

  6. Subjects with other active malignancies within the past 5 years, such as basal or squamous skin cancer, superficial bladder cancer, or breast cancer in situ, that have been completely cured and do not require follow-up treatment are excluded;

  7. Severe autoimmune diseases such as ulcerative colitis, Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus, autoimmune vasculitis, or Wegener's granuloma require long-term (more than 2 months) systemic immunosuppressive therapy, but subjects with the following conditions are admitted:

    Autoimmune hypothyroidism requiring only hormone replacement therapy; Skin disorders that do not require systemic treatment (e.g., eczema, a rash of less than 10% of the body surface);

  8. Subjects with allergic constitution, allergy to immunotherapy or related drugs;

  9. Organ failure; Coronary heart: grades ⅲ and ⅳ;Or hypertension that cannot be controlled by standard treatment, a history of myocarditis or myocardial infarction within one year; Gallo liver: achieves grade C on the Child-Turcotte-Pugh liver function scale; Gallonic kidney: renal failure and uremia; Lung: symptoms of severe respiratory failure; Brain unconsciously: people with consciousness disorder have active brain metastases;

  10. Patients with active bleeding and thrombotic diseases requiring treatment;

  11. Patients with uncontrollable pleural and abdominal effusion requiring clinical treatment or intervention;

  12. Subjects requiring systemic corticosteroids (equivalent to >10 mg prednisone/day) within 14 days prior to enrollment or during the study period;

    The following conditions are allowed to join the group:

    Allow subjects to use topical or inhaled corticosteroids; Allows short-term (≤7 days) use of glucocorticoids for the prevention or treatment of non-autoimmune allergic diseases;

  13. Subject suffering from any mental illness, including dementia, altered mental state, that may affect informed consent and understanding of the relevant questionnaire;

  14. Participated in clinical trials of other drugs or medical devices within 4 weeks;

  15. If the investigator determines that they have a serious and uncontrollable disease or other conditions that may affect their acceptance of this study, they are not considered suitable for this study.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Safety and efficacy of recombinant L-IFN adenovirus injection in relapsed/refractory solid tumors

1.Only 1 lesion: If the tumor volume is less than or equal to 10 cm3, the whole tumor is injected radially and evenly.

If the tumor volume was >10 cm3, the tumor was evenly divided into five quadrants and injected into one quadrant at a time.

2. If there are 2 or more lesions, the most manageable tumor injection is selected; 3. Priority should be given to the body surface metastases that meet the evaluation criteria for tumor efficacy.

4. According to patients' conditions (e.g., patients with thorax and ascites), the investigator and the research group and cooperative units jointly explored other drug administration approaches (e.g., bladder infusion, thorax and abdominal cavity administration,aerosol therapy)

Intratumoral injection: Before use, dilute the product with normal saline according to the size of the tumor to an appropriate volume (10-30% of the total volume of the tumor), or adjust appropriately according to the specific tumor situation, inject directly into the tumor or inject under the guidance of B ultrasound /CT, inject the drug solution into the tumor edge and tumor evenly.

Aerosol therapy: Recombinant Oncolytic Adenovirus L-IFN Injection is delivered to participants via inhalation using a nebulization device.

Andre navne:
  • Onkolytisk virus
  • (YSCH-01)
  • Cancer rettet mod gen-viroterapi (CTGVT) virus (YSCH-01)
  • Replikativt adenovirus
  • Onkolytisk adenovirus

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Dose Limiting Toxicities (DLT)
Tidsramme: Up to 28 days

To define the maximum tolerated dose (MTD) of intratumoral administration of Recombinant L-IFN adenovirus injection in humans with malignant tumors.

Up to 28 days
Safety and tolerability assessed by Adverse Events (AEs)
Tidsramme: Time Frame: Up to 6 months

An AE is any untoward medical occurrence in a subject administered an investigational product (IP), and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IP whether or not considered related to the IP

Time Frame: Up to 6 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of participants with vital sign abnormalities and /or adverse event
Tidsramme: Up to 6 months

Number of participants with potentially clinically significant laboratory values

Up to 6 months
Number of participants with laboratory value abnormalities and/or adverse events
Tidsramme: Up to 6 months

Number of participants with potentially clinically significant laboratory values

Up to 6 months
Presence of neutralizing antibodies of antidrug antibodies (ADAs) development
Tidsramme: Up to 6 months

To evaluate the immunogenicity of Recombinant L-IFN adenovirus injection given as single agent post injection

Up to 6 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Feng Liu, PhD, Shanghai Fengxian District Central Hospital

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

30. november 2021

Primær færdiggørelse (Faktiske)

31. marts 2025

Studieafslutning (Faktiske)

31. december 2025

Datoer for studieregistrering

Først indsendt

20. december 2021

Først indsendt, der opfyldte QC-kriterier

20. december 2021

Først opslået (Faktiske)

6. januar 2022

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

16. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

10. november 2026

Sidst verificeret

1. marts 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • YSCH-01-0000

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .